Prescribing pattern of antidiabetic drugs in urban population of Hyderabad

Abstract

Background: Diabetes mellitus (DM) is a major public health problem in developing countries. Drug utilization study of antidiabetic drugs is of paramount importance to promote rational drug use in patients with DM and to make available valuable information for the health-care team. Aims & Objective:To determine the prescription pattern of drugs used in the treatment of patients with type 2 DM in outpatient general clinics of Hyderabad. Materials and Methods: A retrospective study was carried out by evaluating 600 prescriptions of antidiabetic drugs over a period of 2 month obtained from pharmacy database of five general family clinics. The study assessed prescribing pattern for six classes of antidiabetic drugs: insulin, biguanides, sulfonylureas, glitazones, α-glucosidase inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Results: Of 600 prescriptions evaluated, 349 were of male patients and 251 were of female patients. Frequency of use of antidiabetic drugs as monotherapy was 74.5% and as combination therapy was 24.5%. As monotherapy, sulfonylureas (33%) were the highly prescribed class of antidiabetic drugs followed by biguanides (20%), insulins (11.3%), α-glucosidase inhibitors (4.8%), DPP-4 inhibitors (4%), and glitazones (1.1%). Among individual drugs, metformin (20%) and glimepiride (16.6%) were the maximum prescribed drugs. As combination therapy, metformin + glimepiride (9.3%) and metformin + voglibose (3.8%) are the most commonly prescribed two-drug combinations, and metformin + voglibose + insulin (1.1%) is the most popular three-drug combination. Conclusion: Sulfonylureas was the most commonly prescribed drug class for patients with type 2 DM followed by biguanides. Major limitations of this work include its retrospective nature and the inability to determine the actual patient adherence to therapy.

Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients

“…In one study, it was used in combination with metformin, sulphonylurea and dipeptidyl peptidase-IV inhibitor at 15 mg/day dose 11 . In five studies patients from only inpatient departments were included 12 13 14 15 16 , one study included patients from both inpatient and outpatient departments 17 while 25 studies included patients from outpatient departments only 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 . Pioglitazone was prescribed to 6.5-11 per cent of T2DM patients in inpatient departments 12 13 14 15 16 .…”

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

“…In our study, 67% of drugs prescribed as single-drug regimen and 33% as single drug regimen and multi-drug regimen. In other studies conducted in India were performed in five private clinics of a locality of Hyderabad, 74.5% prescribed as monotherapy, and 24.5% as combination therapy [6].…”

Efficacy and Tolerability of Gliclazide and Metformin in the management of Type-2 Diabetes Mellitus A Comparative Study

“…Globally, in 2010, approximately 285 million people worldwide had DM and it is estimated that more than 438 million people will have DM by 2030. 1 The urban population in developing countries is predicted to be double between 2000 and 2030. The world health organization predicted a 50% increase in deaths from diabetes over next 10 years and by 2030, diabetes will be projected to be the seventh leading cause of death.…”